Loading
Leading pancreatic cancer trialist, including the maintenance PARP-inhibitor and germline-BRCA studies.
Eileen M. O'Reilly holds the Winthrop Rockefeller Chair in Medical Oncology and is Section Head of Hepatopancreaticobiliary and Neuroendocrine Cancers at Memorial Sloan Kettering Cancer Center. She is a leading pancreatic cancer trialist, known for the maintenance PARP-inhibitor and germline BRCA studies in the disease. Her selected paper reports a randomised phase 2 trial of gemcitabine and cisplatin with or without veliparib in pancreatic adenocarcinoma with a germline BRCA or PALB2 mutation. She directs pancreatic and hepatobiliary cancer research at MSK and leads trials in BRCA-mutant pancreatic cancer and NCI cooperative group gastrointestinal studies.
| Title | Journal | Year |
|---|---|---|
| Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation | Journal of Clinical Oncology | 2020 |
One of the most cited trial reports Europe PMC returns for Daraxonrasib in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Every KRAS wild-type pancreatic cancer should be tested for NRG1 fusions because a specific, approved antibody now exists; zenocutuzumab is the first targeted drug approved for a pancreatic cancer driver.
The strongest human evidence that a cancer vaccine can make durable T cells in a tumour with few mutations; the randomised phase 2 IMCODE003 (260 patients, primary completion listed for January 2031) is the test of whether that translates into fewer relapses.
This is the European standard the UK and NHS page for pancreatic cancer is compared against; NICE guideline NG85 (2018) covers the same ground with an older evidence base and a narrower set of funded drugs.
It defines who a homologous recombination result should send to platinum: core-gene and biallelic carriers, germline or somatic, rather than any repair-gene variant.
The document that made biomarker testing part of routine pancreatic cancer care in the United States; the 2018 version it built on fixed the second-line chemotherapy sequence still used in most guidelines.
Gemcitabine plus cisplatin is a validated platinum doublet for BRCA or PALB2 carriers, and the trial explains why PARP inhibitors are used as maintenance after platinum rather than concurrently with it.
Dual checkpoint blockade, which rescued other cold tumours, does not work in unselected pancreatic cancer; combinations must change the microenvironment first.
Shares Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Metastatic Pancreatic Cancer: ASCO Guideline Update, Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, PARP, Olaparib.
Shares Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection, RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer, Memorial Sloan Kettering Cancer Center, Resectable pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Metastatic Pancreatic Cancer: ASCO Guideline Update, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Pancreatic acinar cell carcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Metastatic Pancreatic Cancer: ASCO Guideline Update, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Olaparib, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.